Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Synthetic Biologics Inc (NYSE American:SYN)

Delayed Data
As of 6:30pm ET
 +0.0159 / +3.12%
Today’s Change
Today|||52-Week Range
Health Technology

Company Description

Synthetic Biologics, Inc. is a clinical stage company, which engages in the development of therapeutics to preserve the microbiome to protect and restore the health of patients. Its product portfolio includes SYN-010 and SYN-004. The SYN-010, which is intended to reduce the impact of methane-producing organisms in the gut microbiome to treat an underlying cause of irritable bowel syndrome with constipation. The SYN-004, which is designed to protect the gut microbiome from the effects of certain commonly used intravenous (IV) antibiotics for the prevention of C. difficile infection, antibiotic-associated diarrhea, and the emergence of antimicrobial resistance. The company was founded by Steven H. Kanzer in January 2001 and is headquartered in Rockville, MD.

Contact Information

Synthetic Biologics, Inc.
9605 Medical Center Drive
Rockville Maryland 20850
P:(301) 417-4364
Investor Relations:



Other institutional8.84%
Mutual fund holders4.47%
Individual stakeholders13.67%

Top Executives

Jeffrey Lucero RileyPresident, Chief Executive Officer & Director
Steven A. ShallcrossChief Financial Officer, Secretary & Treasurer
Michael KalekoSenior Vice President-Research & Development
Joseph SlimanChief Medical Officer
Deb MathewsVice President-Medical Affairs